A Phase I/II Study of Allogeneic Umbilical Cord Blood and Umbilical Cord Tissue-Derived Mesenchymal Stromal Cell Infusions in Children With Cerebral Palsy
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 91
- 试验地点
- 2
- 主要终点
- Change in Gross Motor Function Measure (GMFM-66) in Excess of Expected Change
研究概览
简要总结
The main purpose of this study is to estimate change in motor function 12 months after treatment with a single dose of allogeneic umbilical cord blood (AlloCB) or repeated doses of umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) in children with cerebral palsy. In addition, this study will contribute much needed data to the clinical trials community on the natural history of the motor function in CP over short-term (less than 1 year) time periods relevant to the conduct of clinical trials and assess the safety of AlloCB and hCT-MSC infusion in children with cerebral palsy.
详细描述
This study is a phase I/II, prospective, randomized, open-label trial designed to determine the effect size of change in GMFM-66 score in subjects treated with hCT-MSC or allogeneic CB and assess the safety of repeated doses of hCT-MSC in children with cerebral palsy. Children ages 2-5 years with cerebral palsy due to hypoxic ischemic encephalopathy, stroke, or periventricular leukomalacia may be eligible to participate. All participants will ultimately be treated with an allogeneic cell product at some point during the study. Participants will be randomized to one of three arms: (1) the "AlloCB" arm will receive one allogeneic CB infusion at the baseline visit; (2) the "MSC" arm will receive three hCT-MSC infusions, one each at baseline, three months, and six months; (3) the "natural history" arm will not receive an infusion at baseline but will receive an allogeneic CB infusion at 12 months. Motor outcome measures will be assessed at baseline, six-months, and one-year time points. Safety will be evaluated at each infusion visit and remotely for an additional 12 months after the final visit. Duration of study participation will be 24 months from the time of baseline visit. Randomization to treatment arms will be stratified by GMFCS level at study entry and etiology of CP (Stroke vs. Other).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
盲法说明
Every attempt will be made to blind the outcomes assessor.
入排标准
- 年龄范围
- 24 Months 至 60 Months（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥24 months and ≤60 months adjusted age at the time of enrollment.
- •Diagnosis: Unilateral or bilateral hypertonic cerebral palsy secondary to in utero or perinatal stroke/hemorrhage, hypoxic ischemic encephalopathy (including, but not limited to, birth asphyxia), and/or periventricular leukomalacia.
- •Performance status: Gross Motor Function Classification Score levels I - IV
- •Review of brain imaging (obtained as standard of care prior to study entry) does not suggest a genetic condition or brain malformation.
- •Legal authorized representative consent.
排除标准
- •Available qualified autologous cord blood unit.
- •Hypotonic or ataxic cerebral palsy without spasticity.
- •Autism and autistic spectrum disorders.
- •Hypsarrhythmia.
- •Legally blind
- •Intractable seizures causing epileptic encephalopathy.
- •Evidence of a progressive neurologic disease.
- •Has an active, uncontrolled systemic infection or documentation of HIV+ status.
- •Known genetic disease or phenotypic evidence of a genetic disease on physical exam.
- •Concurrent genetic or acquired disease or comorbidity(ies) that could require a future allogeneic stem cell transplant.
- •Requires ventilatory support, including home ventilator, CPAP, BiPAP, or supplemental oxygen.
- •Impaired renal or liver function as determined by serum creatinine >1.5mg/dL and/or total bilirubin >1.3mg/dL except in patients with known Gilbert's disease.
- •Possible immunosuppression, defined as WBC <3,000 cells/mL or absolute lymphocyte count (ALC) <1500 with abnormal T-cell subsets.
- •Patient's medical condition does not permit safe travel.
- •Previously received any form of cellular therapy.
结局指标
主要结局
Change in Gross Motor Function Measure (GMFM-66) in Excess of Expected Change
时间窗: Baseline to 12 months
GMFM-66 is used to evaluate gross motor function in children with cerebral palsy and is scored using a propriety software program called the Gross Motor Ability Estimator that produces an interval level continuous score ranging from 0 to 100. Higher scores indicate better motor function. The primary endpoint in this study was computed from the GMFM-66 score in three steps: 1) The "observed" change in motor function from Baseline to Month 12 was calculated (positive values indicate improvement, negative values indicate reduction, and zero indicates no change) for each participant; and 2) The expected change in motor function was determined for each participant based on published growth curves; and 3) The expected change in GMFM-66 was subtracted from the observed change to yield the final primary outcome. Positive values indicate a greater change than would be expected, zero indicates change as expected, and negative values indicate a smaller amount of change than would be expected.
次要结局
- Number of Adverse Events(12 months)
研究者
Joanne Kurtzberg, MD
MD
Duke University